STTK trades 157.6% below Wall Street's consensus target of $12.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STTK achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Shattuck Labs, Inc. (STTK) has a Wall Street consensus price target of $12.75, based on estimates from 9 covering analysts. With the stock currently trading at $4.95, this represents a potential upside of +157.6%. The company has a market capitalization of $237M.
Analyst price targets range from a low of $7.00 to a high of $18.00, representing a 86% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STTK trades at a trailing P/E of -7.1x. Analysts expect EPS to grow -14.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RCUSArcus Biosciences, Inc. | $2.4B | $24.31 | $31.00 | +27.5% | Buy | — | 18 |
IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
NKTXNkarta, Inc. | $205M | $2.86 | $9.00 | +214.7% | Buy | — | 12 |
CRISCuris, Inc. | $82M | $0.42 | — | — | Buy | — | 18 |
TGTXTG Therapeutics, Inc. | $8.1B | $53.22 | $54.50 | +2.4% | Buy | 38.6x | 13 |
FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
RVMDRevolution Medicines, Inc. | $34.7B | $162.99 | $165.75 | +1.7% | Buy | — | 22 |
Quick answers to the most common questions about buying STTK stock.
The consensus Wall Street price target for STTK is $12.75, representing 157.6% upside from the current price of $4.95. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STTK has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $12.75 implies 157.6% upside from current levels.
STTK's current price is $4.95 with a consensus target of $12.75 (157.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for STTK, while the most conservative target is $7. The consensus of $12.75 represents the median expectation. These targets typically reflect 12-month expectations.
STTK is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STTK stock forecast based on 9 Wall Street analysts shows a consensus price target of $12.75, with estimates ranging from $7 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STTK, with a "Buy" consensus rating and $12.75 price target (157.6% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STTK analyst price targets range from $7 to $18, a 86% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12.75 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.